Fallopian Tube Cancer
📧 Sign up to get email alerts when something new happens for Fallopian Tube Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-27EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC
EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma,…
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
EMA approval · 2026-01-23EMA Authorised: Elahere (mirvetuximab soravtansine) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Elahere (mirvetuximab soravtansine) for ovarian cancer, fallopian tube cancer and peritoneal cancer…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life [NA]
A trial is exploring whether a hand and foot exercise program can reduce chemotherapy-induced peripheral neuropathy and improve quality of l…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating Raludotatug Deruxtecan (R-DXd) in platinum-resistant, high-grade ovarian cancer, primary peritoneal ca…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers [Phase 2]
Phase 2 trial evaluating mirvetuximab soravtansine as monotherapy in platinum-sensitive epithelial ovarian cancer, peritoneal cancer, and fa…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]
Phase 1 study evaluating the combination of Niraparib and Dostarlimab (TSR-042) in BRCA-mutated unresectable or metastatic cancers including…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors [Phase 1]
Phase 1 study of Felmetatug Vedotin (SGN-B7H4V) in advanced solid tumors was terminated.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine [Phase 2]
Phase 2 clinical trial assessing intravenous mirvetuximab soravtansine in platinum-resistant, FR-alpha–high expressing advanced high-grade e…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer [Phase 1]
Phase 1 trial evaluating the combination of Cirtuvivint and Olaparib for BRCA/Homologous Recombination Deficiency–related platinum-resistant…
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer [Phase 2]
A Phase 2 trial of RC88 in platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer has …
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer [Phase 1, Phase 2]
TORL Biotherapeutics is conducting a Phase 1/2 trial (CATALINA-4) to evaluate the safety and initial efficacy of TORL-1-23 given with chemot…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy [NA]
Clinical trial update on prehabilitation care for women with advanced ovarian cancer undergoing neoadjuvant chemotherapy; the study is curre…
-
CLINICAL_TRIALS withdrawal · 2026-01-07Clinical Trial Update: A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating BAT8006 for platinum-resistant epithelial ovarian cancer, fallopian tube cancer, and primary peritonea…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study [NA]
Life on the Go 3 is an automated, personalized physical activity program being studied to improve immune function and clinical outcomes in w…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
The National Cancer Institute-sponsored study collecting malignant ascites, pleural fluid, and blood from people with solid tumors has been …
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian [Phase 1]
A Phase 1 study investigating AZD2014 (an mTORC1/2 inhibitor) or AZD5363 (an AKT inhibitor) in recurrent endometrial and ovarian cancers, wi…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer [NA]
This ClinicalTrials.gov entry describes a Rutgers-led study focused on enhancing coping and communication for women diagnosed with gynecolog…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers [Phase 1]
Phase 1b study evaluating SL-172154 in combination with other agents in platinum-resistant ovarian, fallopian tube, and primary peritoneal c…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. [Phase 2]
A Phase 2 clinical study of TORL-1-23 is evaluating its activity in platinum-resistant ovarian cancer. The trial is currently recruiting acr…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer [Phase 1]
Phase 1 trial evaluating adding ipatasertib to paclitaxel and carboplatin for Stage III/IV ovarian, fallopian tube, and primary peritoneal c…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) [Phase 1, Phase 2]
This Phase 1/2 study tests durvalumab in combination with chemotherapy as frontline treatment for ovarian cancer and related gynecologic can…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer [Phase 1]
Phase 1 study evaluating carboplatin and paclitaxel chemotherapy with nivolumab, with or without ipilimumab, in ovarian cancer including hig…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance
A ClinicalTrials.gov update describes a study evaluating how dietary patterns affect prognosis for ovarian cancer patients during PARP inhib…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment
This completed feasibility trial evaluated saliva-based and remote monitoring approaches for detecting active cytomegalovirus infection and …